HC Wainwright Reiterates Buy Rating for Savara (SVRA)

Savara (NASDAQ:SVRA)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research note issued to investors on Friday. They currently have a $22.00 price target on the stock. HC Wainwright’s price objective would indicate a potential upside of 97.49% from the stock’s previous close.

The analysts wrote, “Valuation and risks to achievement of target price. Our price target of $22/share is based on an equally weighted composite of: (a) $20/share, as a 30x multiple of taxed and diluted $5.02 discounted back to FY18 at 25% (in line with the expected PE multiple and discount rate of an early development stage biotechnology company); and (b) an NPV of $23/share (discounted cash flow analysis using a 12% discount rate and 1.0% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company).””

Other research analysts have also issued reports about the company. BidaskClub raised Savara from a “hold” rating to a “buy” rating in a research report on Wednesday, June 20th. Canaccord Genuity reaffirmed a “buy” rating on shares of Savara in a research report on Thursday, May 10th. Zacks Investment Research raised Savara from a “sell” rating to a “hold” rating in a research report on Saturday, June 23rd. Finally, Evercore ISI started coverage on Savara in a research report on Friday, June 8th. They issued an “outperform” rating and a $40.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $25.44.

Shares of Savara stock traded down $0.38 during trading hours on Friday, reaching $11.14. 366,681 shares of the company’s stock were exchanged, compared to its average volume of 220,708. Savara has a 52-week low of $5.07 and a 52-week high of $17.19. The firm has a market cap of $355.24 million, a PE ratio of -6.33 and a beta of -0.24. The company has a quick ratio of 16.28, a current ratio of 16.28 and a debt-to-equity ratio of 0.16.

Savara (NASDAQ:SVRA) last issued its quarterly earnings results on Thursday, August 9th. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.02). equities research analysts anticipate that Savara will post -1.34 EPS for the current year.

In other news, CEO Robert N. Neville sold 2,737 shares of the stock in a transaction dated Friday, June 8th. The shares were sold at an average price of $12.13, for a total transaction of $33,199.81. Following the transaction, the chief executive officer now owns 402,648 shares of the company’s stock, valued at $4,884,120.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Jaakko Taneli Jouhikainen sold 17,757 shares of the stock in a transaction dated Tuesday, June 12th. The stock was sold at an average price of $12.10, for a total transaction of $214,859.70. Following the transaction, the insider now directly owns 207,688 shares in the company, valued at approximately $2,513,024.80. The disclosure for this sale can be found here. Insiders have sold 47,055 shares of company stock valued at $569,209 over the last 90 days. Insiders own 6.10% of the company’s stock.

Several hedge funds have recently modified their holdings of the company. CFO4Life Group LLC bought a new position in Savara in the first quarter worth about $104,000. DekaBank Deutsche Girozentrale bought a new position in Savara in the first quarter worth about $111,000. UBS Group AG lifted its holdings in Savara by 1,012.8% in the first quarter. UBS Group AG now owns 14,556 shares of the company’s stock worth $133,000 after acquiring an additional 13,248 shares during the last quarter. GSA Capital Partners LLP bought a new position in Savara in the first quarter worth about $134,000. Finally, Sullivan Bruyette Speros & Blaney LLC bought a new position in Savara in the first quarter worth about $147,000. 42.08% of the stock is currently owned by institutional investors and hedge funds.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

Read More: Short Selling Stocks and Day Traders

Analyst Recommendations for Savara (NASDAQ:SVRA)

Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply